Comparing the current results to its competitors, Aptose Biosciences Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.2 %, recorded in the same quarter.
Aptose Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 37.4 %
Aptose Biosciences Inc 's Comment on Competition and Industry Peers
Aptose operates in the highly competitive biotechnology and pharmaceutical industries, where numerous companies engage in similar activities. Competitors include established pharmaceutical companies with greater financial, technical, research and development, marketing, distribution, production, and human resources capabilities than Aptose. Competition also comes from companies seeking partnerships with biotechnology and pharmaceutical firms and academic institutions. Competitive drugs may target different aspects of cancer but can be used in combination therapies with Aptose's drugs. Key factors influencing competitiveness include the stage of development, timing of commercialization, patent protection, safety profiles, and cost-benefit profiles. In November 2021, Aptose licensed exclusive worldwide rights to tuspetinib from Hanmi and holds patents covering tuspetinib and its analogs, providing a strong intellectual property position.
December 12, 2024
In the dynamic field of cancer research, Aptose Biosciences Inc. is making significant strides with its promising therapeutic candidate, Tuspetinib. Recently, the company announced a series of findings that underline the potential of Tuspetinib as a potent option for the treatment of acute myeloid leukemia (AML), particularly refractory and relapsed cases. The data have been shared at prestigious scientific forums, including the European Hematology Association (EHA) Congress and the American Association for Cancer Research (AACR) journal.One notable advancement from Aptose is the preclinical data published in a recent AACR journal, which delineates Tuspetinib s distinct mechanism of action. The studies revea...
In a momentous breakthrough in the field of leukemia treatment, Aptose Biosciences experimental drug Tuspetinib (TUS) has exhibited remarkable effectiveness in an ongoing Phase 1/2 study for patients with relapsed or refractory acute myeloid leukemia (AML). The impressive clinical data from this study was recently presented during the prestigious 2023 ASH Annual Meeting, shedding light on the potential of TUS as a novel therapeutic option for this challenging disease. AML, a cancer of the blood and bone marrow, is notoriously difficult to treat, with relapsed or refractory cases presenting additional complexities. These patients face limited treatment options and often have poor outcomes. Reco...
Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
Aptose Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aptose Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
